Please login to the form below

Not currently logged in
Email:
Password:

Xceleron and Organon sign microdose study agreement

Xceleron collaborates with Organon on a three-compound human microdose study focusing on candidate selection for further clinical development

UK-based contract research organisation Xceleron has revealed a collaboration with Organon, the human healthcare business unit of Netherlands-based Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development.

The three selected drug candidates are all compounds from Organon' gynaecological R&D activities. The purpose of the human microdose study is to assess all important pharmacokinetic properties of the compounds, while confirming the scalability of the microdose to pharmacological dose for these compounds.

Xceleron will use its Accelerator Mass Spectrometry analytical technology to determine human plasma concentrations after microgram administration of the various drug candidates.

Xceleron' founder and CEO Professor Colin Garner said: "We are delighted that Organon has further demonstrated its willingness to adopt innovative approaches to drug development and are proud to add them to Xceleron' rapidly growing, international portfolio of human microdose supporters."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....